JRJulia Rädler

Julia Rädler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Rädler has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhancing the efficacy of siRNA Antibody Oligonucleotide Conjugates (AOCs) through chemical design

    by O. G. Hayes, J. Rädler, E. Filipiak, T. Czapik, S. Roudi, M. Ojansivu, H. Saranya Ilamathi, A. Marquant, Y. Huang, O. P.B. Wiklander, et al.

    Antibody-oligonucleotide conjugates (AOCs) offer a promising solution to delivery challenges of therapeutic oligonucleotides. However, the relationship between their complex chemical architectures and biological activity remains poorly understood, limiting the development of important structure-function relationships. For siRNA-containing AOCs, increasing the siRNA-to-antibody ratio beyond one (drug-to-antibody ratio, DAR>1) reduces potency, attributed to altered pharmacokinetics arising from increased negative charge density. Here, we investigated whether simple chemical modifications could improve AOC efficacy and mitigate limitations associated with higher DAR. Introduction of a single C16 lipid modification to the siRNA significantly enhanced target gene silencing compared to the unmodified AOC. Extending this modification to a DAR2 architecture, in which two siRNAs are conjugated per antibody, restored the loss of activity associated with increasing DAR from 1 to 2. Notably, at an equivalent siRNA dose (1 mg/kg), the DAR2-C16 AOC requires half the amount of antibody while achieving knockdown comparable to the DAR1-C16 AOC. We also developed a charge-balancing ionizable linker (CBIL) designed to partially compensate for the negative charge of siRNA. Incorporation of the CBIL enhanced target gene silencing in heart and skeletal muscle without a corresponding increase in hepatic activity, resulting in a shift toward greater extrahepatic activity relative to liver. Together, these findings demonstrate that chemical modification of both the siRNA payload and antibody-siRNA linker can be used to tune AOC potency and tissue activity, while enabling higher payload loading without compromising efficacy. These results establish chemical design as an important strategy for expanding the architecture and therapeutic potential of AOCs. TOC Graphic:

  • Open Access

    Quantitative Assessment of shRNA Loading and Delivery Efficiency of Engineered Extracellular Vesicles

    by Julia Anna Radler, Giulia Corso, Omnia Elsharkasy, Noriyasu Kamei, Doste Rashid Mamand, Xiuming Liang, Wenyi Zheng, Antje Maria Zickler, Houze Zhou, Samantha Roudi, et al.

    RNA interference (RNAi) therapeutics enable selective silencing of disease-associated genes. Yet, their clinical application remains largely confined to the liver due to extrahepatic delivery constraints of current platforms such as GalNAc conjugates and lipid nanoparticles. Extracellular vesicles (EVs) offer an attractive alternative delivery strategy owing to their biocompatibility, ability to traverse biological barriers, and amenability to engineering. However, EV-mediated RNA delivery is limited by inefficient endogenous RNA loading and poor cytosolic release following uptake. Here, we establish a modular EV-based platform that addresses both challenges by integrating enhanced endogenous shRNA loading with fusogen-mediated cytosolic delivery. Using Argonaute 2 (AGO2)-assisted loading, we substantially increase shRNA copy numbers per vesicle (up to 3.7 copies/EV) and enable quantitative, molecule-resolved assessment of delivery potency. Engineered EVs achieve robust and reproducible shRNA-mediated gene silencing with picomolar IC₅₀ values across multiple cell types and induce significant target knockdown in the mouse brain following intracerebral administration. Together, these findings demonstrate that coordinated engineering of shRNA loading and cytosolic release can overcome key limitations of EV-mediated small RNA delivery.

  • Open Access

    Click Chemistry-Based Strategy for Modular Ligand Attachment to siRNAs: Toward Extrahepatic RNAi

    by Julia Anna Radler, Eliza Filipiak, Antonin Marquant, Miina Ojansivu, Tomasz Czapik, Alyssa Hill, Nina Ahlskog, Samantha Roudi, Cristiana Barradas, Yanjie Huang, et al.

    Efficient extrahepatic delivery of siRNAs remains a major limitation for broadening their therapeutic potential. Using a modular, orthogonal click chemistry platform, we generated 28 siRNA conjugates varying in ligand class, valency, and spatial arrangement. Following systemic administration, fatty acid conjugates — particularly palmitic acid (C16) — outperformed sterol- and phospholipid-based designs in promoting extrahepatic gene silencing, with preferential activity observed in heart and skeletal muscle. Increasing ligand valency through 3′,5′-bis-conjugation generally enhanced activity compared to 5′-mono conjugation. Nevertheless, bis-C22 conjugates showed increased hepatic activity, suggesting a shift in tissue distribution linked to hydrophobicity. Architectural parameters further modulated outcomes: Branched 5′ C16 conjugates, bearing two lipids on one terminus, were markedly less active than their bis counterparts and required short PEG spacers to restore activity. Notably, bis-lipid conjugation strategies that enhanced extrahepatic activity for an siRNA did not translate to an ASO gapmer, underscoring modality-specific constraints. Together, these findings delineate structure-activity relationships and establish bis-fatty-acid conjugation as a robust design principle for achieving extrahepatic RNAi.


  • Open Access

    RNAi delivery platforms : bioconjugates and extracellular vesicles

    by Julia Rädler

    RNA interference (RNAi) therapeutics hold enormous potential for the treatment of genetic and acquired diseases through sequence-specific silencing of virtually any target transcript. Despite the clinical approval of eight siRNA drugs, all rely on N-acetylgalactosamine (GalNAc) conjugation or lipid nanoparticle encapsulation for hepatocyte-targeted delivery, confining the therapeutic scope of RNAi largely to the liver. This thesis addresses this limitation through two delivery platforms: chemically defined siRNA bioconjugates for extrahepatic delivery, and biologically engineered extracellular vesicles (EVs) for efficient intracellular cargo delivery.For conjugate-mediated delivery (Paper I), a modular click chemistry platform was used to generate 28 siRNA conjugates varying in ligand class, valency, and conjugation architecture. Following systemic injection, fatty acid conjugates demonstrated the best extrahepatic delivery potential among the ligand classes evaluated, with bis-conjugation at both termini consistently outperforming mono-conjugates. Within the fatty-acid series, C16-based designs achieved the strongest activity in heart and skeletal muscle, with up to 67% and 50% target knockdown respectively, likely mediated by albumin-assisted tissue access. In contrast, more hydrophobic conjugates such as bis-C22 showed increased hepatic activity, potentially driven by aggregation and preferential lipoprotein association. Importantly, bis-fatty-acid conjugation, despite improving siRNA delivery, did not translate to fully phosphorothioate-modified antisense oligonucleotides, illustrating how oligonucleotide chemistry can impact conjugate-mediated delivery across modalities. Together, these findings provide a framework for rational conjugate design and highlight considerations for extending siRNA therapeutics to extrahepatic tissues following systemic administration.For EV-based delivery (Papers II-IV), this thesis addresses two fundamental bottlenecks for productive intracellular delivery: inefficient luminal cargo loading and endosomal entrapment following uptake. In Paper II, protein cargo was used to demonstrate that neither loading nor endosomal escape alone is sufficient for functional intracellular delivery. The protein of interest was fused to CD63, a widely used EV-sorting scaffold, to direct cargo into the EV lumen, and fusogenic protein VSV-G was incorporated to mediate endosomal escape following uptake. Both elements proved indispensable for functional delivery, with either alone yielding no measurable activity. Notably, since direct fusion to a membrane protein renders cargo tethered and inactive in recipient cells, a pH-sensitive self-cleaving mini-intein was introduced between CD63 and the cargo to liberate it during EV biogenesis, a consideration unique to fusion proteins. While CD63 is a well-established and effective scaffold, the choice of EV-sorting protein is a critical determinant of loading efficiency that had not been comprehensively explored. Paper III therefore established a high-throughput bioluminescence-based assay to systematically screen 244 candidate scaffold proteins. TSPAN2 and TSPAN3 emerged as superior alternatives to CD63, with conserved performance across five producer cell types and under scalable production conditions. Building on these principles, Paper IV applied both the loading and endosomal escape framework to develop an EV-based shRNA delivery platform. Fusing EV-sorting scaffolds to the RNA-binding protein AGO2 enabled substantially enhanced endogenous shRNA loading. TSPAN2-AGO2 emerged as the top-performing construct, reaching 3.7 shRNA copies per vesicle compared to 1.9 for CD63-AGO2 and 0.06 under passive overexpression. Combined with VSV-G-mediated cytosolic delivery, this platform achieved gene silencing with IC50 values in the picomolar range and significant target knockdown in the mouse brain following intrastriatal injection. Functional potency correlated with shRNA copy number per vesicle, and silencing was strictly dependent on VSV-G across all cell types and cargo formats tested, underscoring that both loading efficiency and cytosolic release are critical determinants of EV-mediated RNAi delivery.Together, this thesis contributes to the mechanistic and technical understanding of two distinct RNAi delivery strategies, highlighting both the potential and current limitations of each platform for therapeutic applications beyond the liver.List of scientific papersI. Julia A. Rädler, Eliza Filipiak, Antonin Marquant, Miina Ojansivu, Tomasz Czapik, Alyssa Hill, Nina Ahlskog, Samantha Roudi, Cristiana Barradas, Yanjie Huang, Matthew Wood, Rula Zain, Malgorzata Honcharenko & Samir EL Andaloussi. Click-Chemistry-Based Strategy for Modular Ligand Attachment to siRNAs: Toward Extrahepatic RNAi. [Manuscript]II. Xiuming Liang, Dhanu Gupta, Junhua Xie, Elien Van Wonterghem, Lien Van Hoecke, Justin Hean, Zheyu Niu, Marziyeh Ghaeidamini, Oscar P. B. Wiklander, Wenyi Zheng, Rim Jawad Wiklander, Rui He, Doste R. Mamand, Jeremy Bost, Guannan Zhou, Houze Zhou, Samantha Roudi, H. Yesid Estupiñán, Julia Rädler, Antje M. Zickler, André Görgens, Vicky W. Q. Hou, Radka Slovak, Daniel W. Hagey, Olivier G. de Jong, Aileen Geobee Uy, Yuanyuan Zong, Imre Mager, Carla Martin Perez, Thomas C. Roberts, Dave Carter, Pieter Vader, Elin K. Esbjörner, Antonin de Fougerolles, Matthew J. A. Wood, Roosmarijn E. Vandenbroucke, Joel Z. Nordin & Samir EL Andaloussi. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nature Communications, 2025, 16, 4028. https://doi.org/10.1038/s41467-025-59377-yIII. Wenyi Zheng*, Julia A. Rädler*, Helena Sork, Zheyu Niu, Samantha Roudi, Jeremy P. Bost, André Görgens, Ying Zhao, Doste R. Mamand, Xiuming Liang, Oscar P. B. Wiklander, Taavi Lehto, Dhanu Gupta, Joel Z. Nordin & Samir EL Andaloussi....

  • Open Access

    RNAi delivery platforms : bioconjugates and extracellular vesicles

    by Julia Rädler

    RNA interference (RNAi) therapeutics hold enormous potential for the treatment of genetic and acquired diseases through sequence-specific silencing of virtually any target transcript. Despite the clinical approval of eight siRNA drugs, all rely on N-acetylgalactosamine (GalNAc) conjugation or lipid nanoparticle encapsulation for hepatocyte-targeted delivery, confining the therapeutic scope of RNAi largely to the liver. This thesis addresses this limitation through two delivery platforms: chemically defined siRNA bioconjugates for extrahepatic delivery, and biologically engineered extracellular vesicles (EVs) for efficient intracellular cargo delivery.For conjugate-mediated delivery (Paper I), a modular click chemistry platform was used to generate 28 siRNA conjugates varying in ligand class, valency, and conjugation architecture. Following systemic injection, fatty acid conjugates demonstrated the best extrahepatic delivery potential among the ligand classes evaluated, with bis-conjugation at both termini consistently outperforming mono-conjugates. Within the fatty-acid series, C16-based designs achieved the strongest activity in heart and skeletal muscle, with up to 67% and 50% target knockdown respectively, likely mediated by albumin-assisted tissue access. In contrast, more hydrophobic conjugates such as bis-C22 showed increased hepatic activity, potentially driven by aggregation and preferential lipoprotein association. Importantly, bis-fatty-acid conjugation, despite improving siRNA delivery, did not translate to fully phosphorothioate-modified antisense oligonucleotides, illustrating how oligonucleotide chemistry can impact conjugate-mediated delivery across modalities. Together, these findings provide a framework for rational conjugate design and highlight considerations for extending siRNA therapeutics to extrahepatic tissues following systemic administration.For EV-based delivery (Papers II-IV), this thesis addresses two fundamental bottlenecks for productive intracellular delivery: inefficient luminal cargo loading and endosomal entrapment following uptake. In Paper II, protein cargo was used to demonstrate that neither loading nor endosomal escape alone is sufficient for functional intracellular delivery. The protein of interest was fused to CD63, a widely used EV-sorting scaffold, to direct cargo into the EV lumen, and fusogenic protein VSV-G was incorporated to mediate endosomal escape following uptake. Both elements proved indispensable for functional delivery, with either alone yielding no measurable activity. Notably, since direct fusion to a membrane protein renders cargo tethered and inactive in recipient cells, a pH-sensitive self-cleaving mini-intein was introduced between CD63 and the cargo to liberate it during EV biogenesis, a consideration unique to fusion proteins. While CD63 is a well-established and effective scaffold, the choice of EV-sorting protein is a critical determinant of loading efficiency that had not been comprehensively explored. Paper III therefore established a high-throughput bioluminescence-based assay to systematically screen 244 candidate scaffold proteins. TSPAN2 and TSPAN3 emerged as superior alternatives to CD63, with conserved performance across five producer cell types and under scalable production conditions. Building on these principles, Paper IV applied both the loading and endosomal escape framework to develop an EV-based shRNA delivery platform. Fusing EV-sorting scaffolds to the RNA-binding protein AGO2 enabled substantially enhanced endogenous shRNA loading. TSPAN2-AGO2 emerged as the top-performing construct, reaching 3.7 shRNA copies per vesicle compared to 1.9 for CD63-AGO2 and 0.06 under passive overexpression. Combined with VSV-G-mediated cytosolic delivery, this platform achieved gene silencing with IC50 values in the picomolar range and significant target knockdown in the mouse brain following intrastriatal injection. Functional potency correlated with shRNA copy number per vesicle, and silencing was strictly dependent on VSV-G across all cell types and cargo formats tested, underscoring that both loading efficiency and cytosolic release are critical determinants of EV-mediated RNAi delivery.Together, this thesis contributes to the mechanistic and technical understanding of two distinct RNAi delivery strategies, highlighting both the potential and current limitations of each platform for therapeutic applications beyond the liver.List of scientific papersI. Julia A. Rädler, Eliza Filipiak, Antonin Marquant, Miina Ojansivu, Tomasz Czapik, Alyssa Hill, Nina Ahlskog, Samantha Roudi, Cristiana Barradas, Yanjie Huang, Matthew Wood, Rula Zain, Malgorzata Honcharenko & Samir EL Andaloussi. Click-Chemistry-Based Strategy for Modular Ligand Attachment to siRNAs: Toward Extrahepatic RNAi. [Manuscript]II. Xiuming Liang, Dhanu Gupta, Junhua Xie, Elien Van Wonterghem, Lien Van Hoecke, Justin Hean, Zheyu Niu, Marziyeh Ghaeidamini, Oscar P. B. Wiklander, Wenyi Zheng, Rim Jawad Wiklander, Rui He, Doste R. Mamand, Jeremy Bost, Guannan Zhou, Houze Zhou, Samantha Roudi, H. Yesid Estupiñán, Julia Rädler, Antje M. Zickler, André Görgens, Vicky W. Q. Hou, Radka Slovak, Daniel W. Hagey, Olivier G. de Jong, Aileen Geobee Uy, Yuanyuan Zong, Imre Mager, Carla Martin Perez, Thomas C. Roberts, Dave Carter, Pieter Vader, Elin K. Esbjörner, Antonin de Fougerolles, Matthew J. A. Wood, Roosmarijn E. Vandenbroucke, Joel Z. Nordin & Samir EL Andaloussi. Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors. Nature Communications, 2025, 16, 4028. https://doi.org/10.1038/s41467-025-59377-yIII. Wenyi Zheng*, Julia A. Rädler*, Helena Sork, Zheyu Niu, Samantha Roudi, Jeremy P. Bost, André Görgens, Ying Zhao, Doste R. Mamand, Xiuming Liang, Oscar P. B. Wiklander, Taavi Lehto, Dhanu Gupta, Joel Z. Nordin & Samir EL Andaloussi....

  • Open Access

    Peptide nanoparticles for systemic mRNA delivery in rodents and non-human primates

    by Taavi Lehto, Tõnis Lehto, Helena Sork, Annely Lorents, Julia Rädler, Safa Bazaz, Samantha Roudi, Oskar Gustafsson, Obedoulaye Boukary, Iris Talgre, et al.

    The therapeutic potential of mRNA is vast, and yet translating this potential into effective treatments requires overcoming significant challenges of achieving safe and efficient delivery. This process is hampered by biological barriers that limit cellular uptake, degrade exposed mRNA, and thus necessitate effective endosomal escape to reach the cytoplasm. To address these challenges, we developed a hPep peptide-based nanoparticle (PNP) system that encapsulates mRNA, forming stable and biocompatible particles, which are rapidly taken up by the cells and enable efficient mRNA delivery across various cell culture models. Following systemic administration in mice, lead hPep3/mRNA PNPs achieve broad mRNA expression across multiple tissues, including the lungs, liver, and spleen, and enable effective mRNA delivery to the central nervous system upon local administration. Furthermore, for the first time we established a high-yield (≥70%) microfluidics-based protocol to scale up the production of well-defined, sterile hPep3/mRNA PNP formulations (approximately 70 nm, PDI around 0.170). Most importantly, in a proof-of-concept study in nonhuman primates (NHPs), we demonstrate that hPep PNPs loaded with human erythropoietin (hEPO) mRNA induce dose-dependent expression of hEPO protein in serum, reaching up to 10 ng/ml at 1.0 mg/kg dose, following both single and repeated administration, while remaining systemically well-tolerated. These findings underscore the potential of hPep peptide-based nanoparticles as a versatile platform for mRNA delivery across multiple tissues, highlighting their promise in advancing the development of mRNA therapeutics.

  • Open Access

    Peptide nanoparticles for systemic mRNA delivery in rodents and non-human primates

    by Tõnis Lehto, Helena Sork, Annely Lorents, Julia Rädler, Safa Bazaz, Samantha Roudi, Oskar Gustafsson, Obedoulaye Boukary, Iris R Talgre, Mattias Hällbrink, et al.

    The therapeutic potential of mRNA is vast, and yet translating this potential into effective treatments requires overcoming significant challenges of achieving safe and efficient delivery. This process is hampered by biological barriers that limit cellular uptake, degrade exposed mRNA, and thus necessitate effective endosomal escape to reach the cytoplasm. To address these challenges, we developed a hPep peptide-based nanoparticle (PNP) system that encapsulates mRNA, forming stable and biocompatible particles, which are rapidly taken up by the cells and enable efficient mRNA delivery across various cell culture models. Following systemic administration in mice, lead hPep3/mRNA PNPs achieve broad mRNA expression across multiple tissues, including the lungs, liver, and spleen, and enable effective mRNA delivery to the central nervous system upon local administration. Furthermore, we established a high-yield (≥70%) microfluidics-based protocol to scale up the production of well-defined, sterile hPep3/mRNA PNP formulations (approximately 70 nm, PDI around 0.170). Most importantly, in a proof-of-concept study in nonhuman primates (NHPs), we demonstrate that hPep PNPs loaded with human erythropoietin (hEPO) mRNA induce dose-dependent expression of hEPO protein in monkey serum, reaching up to 10 ng/ml at 1.0 mg/kg dose, following both single and repeated administration, while remaining systemically well-tolerated. These findings underscore the potential of hPep peptide-based nanoparticles as a versatile platform for mRNA delivery across multiple tissues, highlighting their promise in advancing the development of mRNA therapeutics.


  • Top Cited Papers
    Open Access

    Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors

    by Xiuming Liang, Dhanu Gupta, Junhua Xie, Elien Van Wonterghem, Lien Van Hoecke, Justin Hean, Zheyu Niu, Marziyeh Ghaeidamini, Oscar P. B. Wiklander, Wenyi Zheng, et al.

    Intracellular delivery of protein and RNA therapeutics represents a major challenge. Here, we develop highly potent engineered extracellular vesicles (EVs) by incorporating bio-inspired attributes required for effective delivery. These comprise an engineered mini-intein protein with self-cleavage activity for active cargo loading and release, and fusogenic VSV-G protein for endosomal escape. Combining these components allows high efficiency recombination and genome editing in vitro following EV-mediated delivery of Cre recombinase and Cas9/sgRNA RNP cargoes, respectively. In vivo, infusion of a single dose Cre loaded EVs into the lateral ventricle in brain of Cre-LoxP R26-LSL-tdTomato reporter mice results in greater than 40% and 30% recombined cells in hippocampus and cortex respectively. In addition, we demonstrate therapeutic potential of this platform by showing inhibition of LPS-induced systemic inflammation via delivery of a super-repressor of NF-ĸB activity. Our data establish these engineered EVs as a platform for effective delivery of multimodal therapeutic cargoes, including for efficient genome editing.


  • Open Access

    Identification of scaffold proteins for improved endogenous engineering of extracellular vesicles

    by Wenyi Zheng, Julia Rädler, Helena Sork, Zheyu Niu, Samantha Roudi, Jeremy P. Bost, André Görgens, Ying Zhao, Doste R. Mamand, Xiuming Liang, et al.

    Extracellular vesicles (EVs) are gaining ground as next-generation drug delivery modalities. Genetic fusion of the protein of interest to a scaffold protein with high EV-sorting ability represents a robust cargo loading strategy. To address the paucity of such scaffold proteins, we leverage a simple and reliable assay that can distinguish intravesicular cargo proteins from surface- as well as non-vesicular proteins and compare the EV-sorting potential of 244 candidate proteins. We identify 24 proteins with conserved EV-sorting abilities across five types of producer cells. TSPAN2 and TSPAN3 emerge as lead candidates and outperform the well-studied CD63 scaffold. Importantly, these engineered EVs show promise as delivery vehicles in cell cultures and mice as demonstrated by efficient transfer of luminal cargo proteins as well as surface display of different functional entities. The discovery of these scaffolds provides a platform for EV-based engineering.